Joint damage combination approved

Published: 3-Feb-2001


The FDA has approved Centocor's infliximab (Remicade) to be used in conjunction with methotrexate for inhibiting the progression of structural damage in patients with moderately to severely active rheumatoid arthritis.

You may also like